Table 1.

Analysis of 41 lncRNAs showing the most significant diagnostic value for PTC (AUC > 0.90)

Gene_name	AUC	Dysregulation	log2FC	P value	P adjusted
LINC01977	0.97	Up	3.93	1.15E‐68	1.87E‐65
RP11‐363E7.4	0.97	Up	2.01	3.75E‐27	3.15E‐25
RP3‐483K16.4	0.96	Down	−2.97	5.67E‐49	3.46E‐46
RP11‐547D24.1	0.96	Up	3.46	1.55E‐55	1.26E‐52
RUNDC3A‐AS1	0.96	Up	2.13	5.34E‐30	6.36E‐28
AC093609.1	0.96	Down	−2.31	9.37E‐47	4.15E‐44
CTD‐2008L17.2	0.95	Down	−2.62	2.35E‐41	6.74E‐39
HAGLROS	0.95	Up	3.85	4.78E‐24	2.99E‐22
UNC5B‐AS1	0.94	Up	5.17	1.12E‐33	1.82E‐31
LINC01354	0.94	Down	−2.02	4.87E‐19	1.86E‐17
AP000997.3	0.94	Up	3.99	2.62E‐46	1.06E‐43
AC018816.3	0.94	Up	3.19	1.30E‐29	1.40E‐27
AC079630.2	0.94	Up	5.40	7.66E‐87	1.87E‐83
LINC01539	0.94	Down	−2.47	2.83E‐29	2.76E‐27
LRP4‐AS1	0.94	Up	4.30	1.18E‐35	2.14E‐33
RP13‐895J2.3	0.93	Down	−2.14	4.67E‐24	2.96E‐22
RP11‐320N7.2	0.93	Up	3.37	1.08E‐38	2.30E‐36
RP11‐350J20.12	0.93	Up	4.78	4.32E‐42	1.32E‐39
CTC‐255N20.1	0.93	Up	3.23	1.19E‐55	1.16E‐52
RP11‐476D10.1	0.92	Up	6.14	9.69E‐28	8.59E‐26
CTC‐277H1.7	0.92	Up	2.29	3.50E‐31	4.49E‐29
RP11‐230G5.2	0.92	Up	5.57	8.44E‐32	1.18E‐29
AC068138.1	0.91	Down	−2.13	7.33E‐16	1.88E‐14
CTD‐3060P21.1	0.91	Up	2.44	2.74E‐34	4.61E‐32
AC079630.4	0.91	Up	4.04	1.10E‐48	5.97E‐46
RP11‐136I14.5	0.91	Up	2.85	7.90E‐32	1.13E‐29
LINC01770	0.91	Up	3.17	2.13E‐36	4.00E‐34
CTD‐2619J13.13	0.91	Up	4.10	3.26E‐31	4.29E‐29
RP11‐366L20.2	0.91	Up	2.99	5.90E‐44	2.06E‐41
RP11‐221N13.3	0.91	Up	4.78	2.96E‐91	1.44E‐87
CTD‐3014M21.1	0.90	Down	−2.35	6.33E‐40	1.54E‐37
AC007255.8	0.90	Up	5.08	1.33E‐43	4.34E‐41
RP11‐280O1.2	0.90	Up	7.28	8.66E‐65	1.06E‐61
RP11‐44N11.2	0.90	Up	4.31	6.93E‐24	4.17E‐22
RP11‐615I2.2	0.90	Up	2.40	3.14E‐40	8.05E‐38
AC008753.6	0.90	Down	−2.09	2.64E‐18	9.48E‐17
TYMSOS	0.90	Up	2.17	4.00E‐26	3.10E‐24
RP4‐751H13.7	0.90	Down	−2.16	6.12E‐06	3.31E‐05
RP11‐285E9.6	0.90	Up	2.71	1.57E‐31	2.13E‐29
DOCK9‐AS2	0.90	Up	2.10	2.03E‐29	2.02E‐27
TNRC6C‐AS1	0.90	Up	2.65	4.47E‐47	2.18E‐44

AUC, area under the ROC curve; lncRNAs, Long noncoding RNAs; PTC, papillary thyroid carcinoma.